scholarly journals PS-042c Is Low-dose Combined Oral Contraceptives Use Associated To Lower Bone Mineral Content Variation In Adolescents Over A One-year Period?

2014 ◽  
Vol 99 (Suppl 2) ◽  
pp. A127.1-A127
Author(s):  
TB Goldberg ◽  
TP Biason ◽  
CS Kurokawa ◽  
MR Moretto ◽  
AS Teixeira ◽  
...  
Keyword(s):  
Bone Mineral Content ◽  
Bone Mineral ◽  
Oral Contraceptives ◽  
Mineral Content ◽  
Low Dose ◽  
Combined Oral Contraceptives ◽  
Content Variation ◽  
One Year

scholarly journals Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Talita Poli Biason ◽  
Tamara Beres Lederer Goldberg ◽  
Cilmery Suemi Kurokawa ◽  
Maria Regina Moretto ◽  
Altamir Santos Teixeira ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Bone Mineral Content ◽  
Bone Mineral ◽  
Mineral Content ◽  
Low Dose ◽  
Contraceptive Use ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use ◽  
Content Variation

Effects of One-Year Adjuvant Treatment with Tamoxifen on Bone Mineral Density in Postmenopausal Breast Cancer Women

1996 ◽  
Vol 82 (1) ◽  
pp. 65-67 ◽  
Author(s):  
Sandro Barni ◽  
Paolo Lissoni ◽  
Gabriele Tancini ◽  
Antonio Ardizzoia ◽  
Marina Cazzaniga
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Mineral Content ◽  
Bone Mineral ◽  
Adjuvant Treatment ◽  
Mineral Content ◽  
Postmenopausal Breast Cancer ◽  
Mineral Density ◽  
One Year

In this study, the authors have analyzed the possible effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Bone mineral content was studied by photon absorptiometry (I-125), whereas bone balance was analyzed indirectly by serum PTH, osteocalcin, calcitonin, calcium and alkaline phosphatase levels. Bone mineral content and serum bone-related substances were measured before starting treatment and after one year. Results were analyzed using Student's t test for paired data. No difference was found between the two measurements for bone mineral content, PTH, calcitonin, calcium and alkaline phosphatase levels. Measurements at entry and after one year of treatment showed a statistically significant difference ( P < 0.001) only for osteocalcin. In accordance with other authors, we can conclude that treatment with tamoxifen does not cause an increase in menopausal bone resorption. The finding that osteocalcin levels decreased after one year of therapy with tamoxifen is interesting, but further studies are necessary to clarify the role of such levels in predicting a turnover of bone balance towards osteoblastic activity.

148. Effect of Low-Dose Combined Oral Contraceptives on Bone Mineral Density in Adolescents: A 1-Year Follow-Up

2013 ◽  
Vol 52 (2) ◽  
pp. S92
Author(s):  
Talita Poli Biason ◽  
Maria Regina Moretto ◽  
Cristina Fortes Rezende ◽  
Cilmery Suemi Kurokawa ◽  
Altamir Teixeira ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Mineral Density ◽  
Combined Oral Contraceptives

Long-Term Low-Dose Glucocorticoid Therapy in Hyperandrogenized Women: Utility and Effects on Bone Mineral Content and Hypothalamic-Pituitary-Adrenocorticai Function

1991 ◽  
Vol 35 (3-4) ◽  
pp. 142-145 ◽  
Author(s):  
Liliana N. Contreras ◽  
L. Rizzo ◽  
R.M. G&oacute;mez ◽  
J.R. Zanchettal ◽  
Maria A. Rossi ◽  
...  
Keyword(s):  
Bone Mineral Content ◽  
Bone Mineral ◽  
Mineral Content ◽  
Low Dose ◽  
Glucocorticoid Therapy

Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures

1990 ◽  
Vol 123 (1) ◽  
pp. 14-18 ◽  
Author(s):  
H. Resch ◽  
P. Pietschmann ◽  
E. Krexner ◽  
W. Woloszczuk ◽  
R. Willvonseder
Keyword(s):  
Bone Mineral Content ◽  
Replacement Therapy ◽  
Bone Mineral ◽  
Mineral Content ◽  
Single Photon ◽  
Single Photon Absorptiometry ◽  
Photon Absorptiometry ◽  
One Year ◽  
Hydroxyproline Excretion ◽  
Peripheral Bone

Abstract. A double-blind, placebo-controlled study on 31 patients with osteoporotic spine fractures was performed in order to assess the effects of one-year cyclical estrogen/gestagen replacement therapy (Trisequens, Novo) on peripheral bone mineral content and bone turnover. Bone mineral content was measured by single-photon absorptiometry with 125I before, and 6 and 12 months after start of therapy. Calcium, phosphate, alkaline phosphatase, parathyroid hormone, calcidiol, calcitonin and 2-hour urinary hydroxyproline excretion were measured to evaluate bone turnover. After 12 months, forearm bone mineral content showed a significant increase (p<0.02) in the treatment group, whereas in the control group no statistically significant change in peripheral bone mass was observed. Parameters of bone metabolism showed a decrease in hydroxyproline excretion (p<0.02) as well as alkaline phosphatase (p<0.01) and no changes in parathyroid hormone, calcidiol, and calcitonin. These results demonstrate that one-year cyclical estrogen/gestagen replacement therapy improves peripheral bone mineral content measured by single-photon absorptiometry. This effect appears to be induced by an inhibition of bone resorption.

Sign in / Sign up

Export Citation Format

Share Document